Literature DB >> 6852971

Formation and growth of multicellular spheroids of human origin.

J Carlsson, K Nilsson, B Westermark, J Pontén, C Sundström, E Larsson, J Bergh, S Påhlman, C Busch, V P Collins.   

Abstract

Different types of human cells which normally grow as monolayers or suspension cultures were tested for their capacity to form and grow as spheroids. Sixteen out of the 27 tested tumour cell lines formed spheroids. Nearly all of these spheroids also grew. With only two exceptions the doubling times were longer when the tumour cells grew as spheroids than when they grew in conventional mass culture. Eleven out of 13 tested human non-tumour cells formed small spheroids but of these only the spheroids of lymphoid origin could grow. These lymphoid cells grew faster when aggregated to spheroids than when in single-cell suspension culture. None of the other non-tumour cells, which normally grew as monolayers, could grow as spheroids. The normally monolayer-cultured tumour cells formed symmetrical spheroids with smooth surfaces while the normally suspension-cultured cells formed irregular spheroids with rough surfaces. All large spheroids had a necrotic centre surrounded by a shell of viable cells. The thickness of the viable cell layer varied depending on cell type. The shape and organization of cells within the spheroids also varied largely. The results show that many types of human cells can be cultured as spheroids and that a wide spectrum of morphological appearances and growth rates can be obtained.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852971     DOI: 10.1002/ijc.2910310502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.

Authors:  Sweta K Gupta; Elisa A Torrico Guzmán; Samantha A Meenach
Journal:  Int J Cancer       Date:  2017-08-18       Impact factor: 7.396

2.  Three-dimensional culture of human tumor cells under standardized medium conditions.

Authors:  J H Schwachofer; J Hoogenhout; H B Kal
Journal:  Cytotechnology       Date:  1991-03       Impact factor: 2.058

3.  Culture of human main pancreatic duct epithelial cells.

Authors:  D Oda; C E Savard; T D Nguyen; E R Swenson; S P Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-03       Impact factor: 2.416

4.  Heterogeneic modulation of malignant behavior in human glioma cells in defined and serum-containing media.

Authors:  H K Haugland; O B Tysnes
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

5.  Agglomeration to nodules modulates human arterial smooth muscle cells to distinct postinjury phenotype via foam cell transition.

Authors:  S Björkerud
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

Review 6.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

7.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

Authors:  T Nederman; J Carlsson
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture.

Authors:  L Fjellbirkeland; R Bjerkvig; O D Laerum
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

10.  Human immunodeficiency virus can productively infect cultured human glial cells.

Authors:  C Cheng-Mayer; J T Rutka; M L Rosenblum; T McHugh; D P Stites; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.